NCAPG and hepatocellular carcinoma: LY294002, a PI3K inhibitor, eliminates the role of NCAPG in promoting HCC cell proliferation, while 740Y-P, a PI3K activator, resists the effects of FOXO6 knockdown on the cytotoxicity and glycolysis of paclitaxel in HCC cells (15, 122).